Lanadelumab is a prescription medicine used to treat hereditary angioedema (HAE) in people 12 years of age and older. It is a monoclonal antibody that works by blocking the activity of a protein called plasma kallikrein, which helps reduce the frequency and severity of HAE attacks. Lanadelumab is given as an injection under the skin (subcutaneous injection) every 2 weeks. Common side effects include injection site reactions, headache, upper respiratory tract infection, and abdominal pain.
Lanadelumab, sold under the brand name Takhzyro, is a medication specifically designed to address hereditary angioedema (HAE). Here's a breakdown of its key features:
Type of medication: Lanadelumab is a human monoclonal antibody. This means it's a lab-made protein designed to target a specific molecule in the body.
How it works: Lanadelumab works by targeting a protein called plasma kallikrein. In people with HAE, uncontrolled kallikrein activity leads to excessive production of bradykinin, a chemical that causes swelling. Lanadelumab binds to kallikrein, preventing it from creating bradykinin and thereby reducing swelling attacks.
Condition it treats: Lanadelumab is used to prevent attacks of hereditary angioedema (HAE) in adults and children 2 years of age and older. HAE is a rare genetic disorder that causes episodes of swelling in various body parts, including the hands, feet, face, airway, or intestines.
Dosage and administration: Lanadelumab is administered via subcutaneous injection (under the skin) by a healthcare professional or self-administered after proper training. The dosage and frequency of injection depend on the individual's response and age.
Important considerations:
- Lanadelumab is a prescription medication and should only be taken under the supervision of a doctor experienced in managing HAE.
- It's not intended for treating acute HAE attacks; it's for preventing future occurrences.
- Lanadelumab may cause side effects, including injection site reactions, headache, fatigue, and upper respiratory tract infections.
- It can interact with other medications, so it's crucial to inform your doctor about all medications you take before starting Lanadelumab.
Additional information:
- Lanadelumab was the first medication approved for the preventive treatment of HAE.
- It offers a significant improvement for people with HAE by reducing the frequency and severity of swelling attacks.